For the Inventor, By the Inventor

Enter assignee name

Needham, MA, United States of America

Avant Immunotherapeutics, Inc.

USPTO Granted Patents = 20

CIPO Patents = 3

Forward Citations = 337

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Lawrence J Thomas (4 out of 12 patents)

Charles William Rittershaus (4 out of 23 patents)

Henry C Marsh (3 out of 17 patents)

4. Sharon A Jenkins (3 out of 6 patents)

5. Lloyd B Klickstein (2 out of 13 patents)

6. Michael F Concino (2 out of 27 patents)

7. Roy Curtiss, Iii (2 out of 54 patents)

8. Steven A Tinge (2 out of 4 patents)

9. Douglas T Fearon (2 out of 7 patents)

10. Gerald R Carson (2 out of 6 patents)

11. Savvas C Makrides (2 out of 7 patents)

12. Winnie W Wong (2 out of 6 patents)

13. Stephen H Ip (2 out of 28 patents)

14. Lendon G Payne (2 out of 8 patents)

15. Victor Bronshtein (1 out of 13 patents)

20 patents: Sort by Forward Citations

1. 7341860 - Regulated antigen delivery system (RADS) (2008-03-11),

2. 7078036 - Modulation of cholesteryl ester transfer protein (CETP) activity (2006-07-18),

3. 7074407 - Method for increasing HDL cholesterol level (2006-07-11),

4. 6884866 - Bulk drying and the effects of inducing bubble nucleation (2005-04-26),

5. 6846808 - Plasmid-based vaccine for treating atherosclerosis (2005-01-25),

6. 6841373 - Herpes virus complementing cell line (2005-01-11),

7. 6780405 - Regulated antigen delivery system (RADS) (2004-08-24),

8. 6555113 - Modulation of cholesteryl ester transfer protein (CETP) activity (2003-04-29),

9. 6410022 - Modulation of cholesteryl ester transfer protein (CETP) activity (2002-06-25),

10. 6376235 - IVI-2, IVI-3 and IVI-4 loci of Enterococcus faecalis polynucleotide, polypeptides and method of use therefor (2002-04-23),

11. 6316604 - Human C3b/C4b receptor (CR1) (2001-11-13),

12. 6284533 - Plasmid-based vaccine for treating atherosclerosis (2001-09-04),

13. 6261573 - Immunoadjuvants (2001-07-17),

14. 6207171 - Polyphosphazene microspheres (2001-03-27),

15. 6193979 - Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands (2001-02-27),

Avant Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing novel immunotherapies for cancer and infectious diseases. The company's innovative therapies aim to harness the power of the immune system to target and destroy disease cells. With a strong pipeline of candidates and a commitment to advancing medical science, Avant Immunotherapeutics is at the forefront of cutting-edge research in the field of immunotherapy.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

20 Patents

#6 in Needham, MA

#942 in Massachusetts

#15,890 in US

#30,364 in the World

Needham, MA, United States of America

Avant Immunotherapeutics, Inc.

Forward Citations = 337

41 inventors:

Lawrence J Thomas (4 out of 12 patents)

Charles William Rittershaus (4 out of 23 patents)

Henry C Marsh (3 out of 17 patents)

4. Sharon A Jenkins (3 out of 6 patents)

5. Lloyd B Klickstein (2 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…